Updates in the Management of Primary Mediastinal B Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Aug 21:S2152-2650(23)00274-4. doi: 10.1016/j.clml.2023.08.014. Online ahead of print.ABSTRACTPrimary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under i...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Charbel Soueidy Hampig Raphael Kourie Source Type: research
Multiple Myeloma in Young Patients: A Scoping Review
Clin Lymphoma Myeloma Leuk. 2023 Aug 28:S2152-2650(23)00277-X. doi: 10.1016/j.clml.2023.08.019. Online ahead of print.ABSTRACTData on the disease course, presenting features, outcomes, and prognosis of younger patients with multiple myeloma (MM) are lacking. Younger patients with MM have historically been considered to have better outcomes primarily based on better tolerance of treatment and lack of medical comorbidities, but the specific age range of this population has not been uniformly defined. Given the lack of consistent data reporting in patients considered to be young MM patients, we performed a scoping review to h...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Mary Steinbach Karun Neupane Muhammad Aziz Wade Lee-Smith Kelley Julian Amandeep Godara Brian McClune Amar H Kelkar Douglas Sborov Ghulam Rehman Mohyuddin Source Type: research
Updates in the Management of Primary Mediastinal B Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Aug 21:S2152-2650(23)00274-4. doi: 10.1016/j.clml.2023.08.014. Online ahead of print.ABSTRACTPrimary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under i...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Charbel Soueidy Hampig Raphael Kourie Source Type: research
Multiple Myeloma in Young Patients: A Scoping Review
Clin Lymphoma Myeloma Leuk. 2023 Aug 28:S2152-2650(23)00277-X. doi: 10.1016/j.clml.2023.08.019. Online ahead of print.ABSTRACTData on the disease course, presenting features, outcomes, and prognosis of younger patients with multiple myeloma (MM) are lacking. Younger patients with MM have historically been considered to have better outcomes primarily based on better tolerance of treatment and lack of medical comorbidities, but the specific age range of this population has not been uniformly defined. Given the lack of consistent data reporting in patients considered to be young MM patients, we performed a scoping review to h...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Mary Steinbach Karun Neupane Muhammad Aziz Wade Lee-Smith Kelley Julian Amandeep Godara Brian McClune Amar H Kelkar Douglas Sborov Ghulam Rehman Mohyuddin Source Type: research
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 16, 2023 Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 16, 2023 Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 16, 2023 Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
Descriptive Analysis and Factors Influencing Survival in Patients With Primary Cutaneous Gamma-Delta T Cell Lymphoma. A Retrospective National Cancer Database Study
CONCLUSION: Socioeconomic disparities significantly impact access to healthcare and are of particular importance in rare lymphomas.PMID:37690902 | DOI:10.1016/j.clml.2023.08.015 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Prashanth Ashok Kumar Abirami Sivapiragasam Dongliang Wang Danning Huang Teresa Gentile Source Type: research
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
CONCLUSIONS: Significant disparities in cancer care exist among geographic locations. Geographic differences in survival appear more prominent when highly effective therapies are available.PMID:37690903 | DOI:10.1016/j.clml.2023.08.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Kiyomi Morita Hagop Kantarjian Guillermo Garcia-Manero Elias Jabbour Farhad Ravandi Marina Konopleva Gautam Borthakur William Wierda Naval Daver Koichi Takahashi Courtney DiNardo Guillermo Montalban Bravo Ghayas C Issa Sherry A Pierce Kelly A Source Type: research
Descriptive Analysis and Factors Influencing Survival in Patients With Primary Cutaneous Gamma-Delta T Cell Lymphoma. A Retrospective National Cancer Database Study
CONCLUSION: Socioeconomic disparities significantly impact access to healthcare and are of particular importance in rare lymphomas.PMID:37690902 | DOI:10.1016/j.clml.2023.08.015 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Prashanth Ashok Kumar Abirami Sivapiragasam Dongliang Wang Danning Huang Teresa Gentile Source Type: research
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
CONCLUSIONS: Significant disparities in cancer care exist among geographic locations. Geographic differences in survival appear more prominent when highly effective therapies are available.PMID:37690903 | DOI:10.1016/j.clml.2023.08.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Kiyomi Morita Hagop Kantarjian Guillermo Garcia-Manero Elias Jabbour Farhad Ravandi Marina Konopleva Gautam Borthakur William Wierda Naval Daver Koichi Takahashi Courtney DiNardo Guillermo Montalban Bravo Ghayas C Issa Sherry A Pierce Kelly A Source Type: research
Descriptive Analysis and Factors Influencing Survival in Patients With Primary Cutaneous Gamma-Delta T Cell Lymphoma. A Retrospective National Cancer Database Study
CONCLUSION: Socioeconomic disparities significantly impact access to healthcare and are of particular importance in rare lymphomas.PMID:37690902 | DOI:10.1016/j.clml.2023.08.015 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Prashanth Ashok Kumar Abirami Sivapiragasam Dongliang Wang Danning Huang Teresa Gentile Source Type: research
